A systematic review and meta-analysis published in Frontiers in Endocrinology on October 30, 2025 — registered with PROSPERO under protocol CRD42023369270 and conducted in accordance with PRISMA guidelines — has produced the most comprehensive assessment to date of yerba mate's effects on glycemic control and metabolic health. The review screened 1,294 studies, ultimately including 13 randomized controlled trials that met its inclusion criteria. The findings suggest a nuanced picture: yerba mate appears to have clinically meaningful glycemic benefits specifically in pre-diabetic populations, while showing no significant effects on lipid parameters or body composition.
The Glycemic Findings
The meta-analysis identified statistically significant decreases in three key glycemic markers among pre-diabetic patients who consumed yerba mate: postprandial glucose (blood sugar levels after eating), glycated hemoglobin (HbA1c, which reflects average blood glucose over the preceding 2–3 months), and the HOMA index (Homeostatic Model Assessment, a measure of insulin resistance). These are the three parameters that matter most in the pre-diabetes to diabetes progression: postprandial glucose spikes drive glycemic excursions that damage vascular endothelium, elevated HbA1c indicates chronic glycemic dysregulation, and a rising HOMA index signals increasing insulin resistance — the hallmark pathophysiology of type 2 diabetes.
What Did Not Change
Equally important is what the meta-analysis did not find. Yerba mate consumption showed no significant effects on triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, fasting glucose, fasting insulin, waist circumference, or body mass index across the 13 included trials. This null result for fasting glucose — in contrast to the positive results for postprandial glucose — is notable: it suggests that yerba mate may be modulating the body's acute glucose response to food (possibly through effects on carbohydrate absorption or postprandial insulin secretion) rather than altering baseline glucose metabolism. The absence of lipid effects is consistent with some prior studies but contradicts others, underscoring the limitations of heterogeneous trial designs across different populations.
Adverse Events and Clinical Relevance
The review documented adverse events reported across the 13 trials, which included mucosal irritation, insomnia, tachycardia, angina, headache, and gastrointestinal discomfort. These events are consistent with the known pharmacological profile of yerba mate's methylxanthine content (caffeine, theobromine, theophylline) and with the thermal irritation associated with traditional hot-water preparation methods. The tachycardia and angina events, while rare, are clinically significant and reinforce the standard medical recommendation that patients with cardiovascular conditions should exercise caution with caffeinated beverages.
For the yerba mate industry, the Frontiers in Endocrinology meta-analysis provides the strongest evidence to date for a specific, delimited health claim: that yerba mate consumption may help manage postprandial glucose and improve glycemic markers in individuals with pre-diabetes. This is a considerably more precise and defensible claim than the general 'metabolic health' or 'weight management' benefits that are frequently attributed to yerba mate in marketing materials. If confirmed by larger, longer-duration trials, this finding could position yerba mate as a dietary adjunct in pre-diabetes management — a rapidly growing clinical category, given that the International Diabetes Federation estimates that 541 million people globally have impaired glucose tolerance.